Cyclosporine A Plus Low-steroid Treatment in COVID-19 Pneumonia : Utility of Low Doses of Corticosteroids and Cyclosporine Combined With Enoxaparin, in Patients With COVID-19 Pneumonia at the ISSSTE Regional Hospital, Puebla, During the Contingency Period Due to the SARS-Cov2 Pandemic
Methods: Single-center pilot study included PCR+ SARS-CoV2-patients, hospitalized from April to May 2020 in Puebla, Mexico. Comparative treatment with steroids plus CsA or steroids. Mild, moderate or severe pneumonia was measured by clinical, laboratory tests, lung damage score by computed tomography, and score for clinical improvement. Death rate was evaluated at 28 days..
Medienart: |
Klinische Studie |
---|
Erscheinungsjahr: |
2020 |
---|---|
Erschienen: |
2020 |
Enthalten in: |
ClinicalTrials.gov - (2020) vom: 07. Sept. Zur Gesamtaufnahme - year:2020 |
---|
Sprache: |
Englisch |
---|
Links: |
Volltext [kostenfrei] |
---|
Themen: |
610 |
---|
Anmerkungen: |
Source: Link to the current ClinicalTrials.gov record., First posted: September 7, 2020, Last downloaded: ClinicalTrials.gov processed this data on June 14, 2021, Last updated: June 15, 2021 |
---|
fisyears: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
CTG003509001 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | CTG003509001 | ||
003 | DE-627 | ||
005 | 20230425212715.0 | ||
007 | cr uuu---uuuuu | ||
008 | 210408s2020 xx |||||o 00| ||eng c | ||
035 | |a (DE-627)CTG003509001 | ||
035 | |a (UBBS_Klinische_Studien)NCT04540926 | ||
035 | |a (UBBS_Klinische_Studien)135.2020 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
245 | 1 | 0 | |a Cyclosporine A Plus Low-steroid Treatment in COVID-19 Pneumonia |b Utility of Low Doses of Corticosteroids and Cyclosporine Combined With Enoxaparin, in Patients With COVID-19 Pneumonia at the ISSSTE Regional Hospital, Puebla, During the Contingency Period Due to the SARS-Cov2 Pandemic |
264 | 1 | |c 2020 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a Computermedien |b c |2 rdamedia | ||
338 | |a Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Source: Link to the current ClinicalTrials.gov record., First posted: September 7, 2020, Last downloaded: ClinicalTrials.gov processed this data on June 14, 2021, Last updated: June 15, 2021 | ||
520 | |a Methods: Single-center pilot study included PCR+ SARS-CoV2-patients, hospitalized from April to May 2020 in Puebla, Mexico. Comparative treatment with steroids plus CsA or steroids. Mild, moderate or severe pneumonia was measured by clinical, laboratory tests, lung damage score by computed tomography, and score for clinical improvement. Death rate was evaluated at 28 days. | ||
650 | 2 | |a Pneumonia | |
650 | 4 | |a Medical Condition: COVID 19 Pneumonia | |
650 | 4 | |a Study Type: Interventional | |
650 | 4 | |a Recruitment Status: Not yet recruiting | |
650 | 4 | |a Phase: Phase 1/Phase 2 | |
650 | 4 | |a 610 | |
773 | 0 | 8 | |i Enthalten in |t ClinicalTrials.gov |g (2020) vom: 07. Sept. |
773 | 1 | 8 | |g year:2020 |g day:07 |g month:09 |
856 | 4 | 0 | |u https://clinicaltrials.gov/show/NCT04540926 |z kostenfrei |3 Volltext |
912 | |a GBV_CTG | ||
912 | |a SSG-OLC-PHA | ||
951 | |a AR | ||
952 | |j 2020 |b 07 |c 09 |